PharmaNest, a leader in high-resolution, single-fiber quantitative Digital Pathology and Artificial Intelligence, showcases the performance of its FibroNest Ph-FCS digital biomarker for quantifying fibrosis severity and its clinical utility in Phase 2 and Phase 3 studies for patients with Metabolic Associated Steatohepatitis (MASH).

A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.

PharmaNest, a leader in high resolution quantitative Digital Pathology and Artificial Intelligence, announces today the launch new quantitative tissue panels to properly quantify tissue injury and inflammation in the context of multiple fibrotic conditions, from discovery models to clinical development. Such spatially resolved datasets can be fused with other spatially resolved biology methods.

PharmaNest, a leader in high resolution, single-fiber, quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest Ph-FCS continuous fibrosis biomarker for the quantification of the severity of fibrosis and prognostics of liver related clinical events in NASH.

New digital pathology, quantitative image analysis and quantitative AI method for liver tissues is presented for the continuous assessment of the histological phenotype(s) of fibrosis, including severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid models, NASH rodent models, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021

Introduction of key technology to accelerate NASH drug discovery by combining 3D disease models and automated AI-based fibrosis quantification

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and regression of Fibrosis in human in-vitro 3D NASH Spheroid models and for the automated classification of post-transplant patients in F4 Fibrosis Stage with and without Hepatocellular carcinoma (HCC) at the Liver Meeting Digital Experience 2020

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in pre-clinical tissues and adult NASH biopsies at the Digital International Liver CongressTM 2020

New image analysis data of tissues with FibroNest™ is presented for the continuous assessment of the severity and progression of fibrosis in Kidney and Lung preclinical models at the Fibrosis and Tissue Repair 2020 Keystone Symposium.

FibroNest image analysis tool provides the most advanced cloud-based phenotypic image analysis and translational platform for the automated quantification of fibrosis across multiple fibrotic conditions and organs for drug discovery and drug development projects.

New image analysis data of biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in both adult and pediatric cohorts at the Liver Meeting® 2019.

Appointment reflects Glauconix Biosciences' readiness to expand their commercial footprint and business verticals in the field of ophthalmology and beyond

FibroNest cloud-based image analysis tool provides the most advanced phenotypic image analysis and translational platform for the automated quantification of fibrosis and steatosis for NASH and for other fibrotic conditions in drug discovery and drug development projects.

Study confirms intraocular pressure-lowering effects of cannabinoid-based therapeutic, proving promising novel treatment for glaucoma

In a new important research study out of the UK, scientists found that the specific form of Modified Citrus Pectin developed by Isaac Eliaz, M.D. interrupts deadly kidney fibrosis by binding to galectin-3 molecules.